Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 57 Stable global insulin market growth and Novo Nordisk sustains global volume market share leadership Global insulin market Global modern and new-generation insulin volume market shares Device penetration Modern insulin penetration¹ tMU CAGR volume¹: 4.6% Penetration 500 CAGR value¹: 14.3% 100% 60% 50% 400 80% 40% 300 60% MI and NGI² 30% 200 Market value³: bDKK 2,645 - 40% 20% 100 Human insulin 20% 10% Market value³: bDKK 286 0 0% 0% Aug 2013 Aug 2018 1 CAGR for 5-year period; 2 MI: Modern insulin; NGI: New-generation insulin 3 Annual value of total insulin class. Note: Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA monthly MAT Aug, 2018 volume and value (DKK) figures changing diabetes® - Novo Nordisk Sanofi Eli Lilly Aug 2013 Note: Data is sensitive to changes in IQVIA data collection and reporting methodology, does not add up to 100% as only selected pharmaceutical companies are included Source: IQVIA monthly MAT Aug, 2018 volume figures 45% 32% 21% Aug 2018 novo nordisk

View entire presentation